The Weekly Roundup: September 8-12

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Comparing Corticosteroids vs. JAK Inhibitors Post-NCES Transplantation for Vitiligo

New findings reveal the effectiveness of corticosteroids and JAK inhibitors post-NCES transplantation for vitiligo, highlighting varied repigmentation responses.

Balancing Efficacy and Tolerability in Retinoid Therapy

Novel formulations like retinal-infused exosomes represent an evolution rather than a replacement of retinoid therapy.

Subtype-Specific Insights into Melanoma in Iceland

Greater awareness of UV risks and stricter sun protection have contributed to declining invasive melanoma rates.

Delgocitinib Now Available in the US for CHE

LEO Pharma's delgocitinib cream for chronic hand eczema is now available to prescribe in the US.

Medicus Moves Forward in UAE Trial for Novel, Non-Invasive BCC Therapy

Medicus Pharma has initiated a phase 2 trial in the UAE for a non-invasive BCC treatment, aiming to revolutionize skin cancer care.

Putting Progress Into Practice for Patients With Vitiligo: Part 3

In part 3 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Topical JAK Inhibitor Shows Rapid Repigmentation in NSV

Forty percent of participants achieved at least a 75% reduction in facial vitiligo scores.

ASCEND Trial Reports Long-Term Safety of Amgen’s Rocatinlimab in Atopic Dermatitis Patients

Phase 3 topline results reveal rocatinlimab's promising safety and efficacy for moderate to severe AD, targeting the OX40 receptor.

Understanding Family Planning Concerns in Patients with Psoriasis

New insights reveal psoriasis patients' challenges with family planning and pregnancy, highlighting the need for better information and support from healthcare providers.

Understanding Isotretinoin's Anti-Inflammatory Mechanism Through Cytokine Levels

Isotretinoin significantly reduces inflammatory cytokines IL-8, IL-36, and TWEAK in acne patients, promoting long-term acne remission and healing.

Journal Digest: September 10, 2025

This review of the latest dermatologic studies highlights new research on novel image fusion for tongue SCC, persistent nodules following HA fillers, rice bran extract for wound healing, and more.

What Works for Patients with Alopecia Areata

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

Obagi Medical Expands Into Fillers Following FDA Approval

The new product expands Obagi Medical’s portfolio beyond skin care into injectables.

Sanofi's OX40L Inhibitor Amlitelimab Shows Positive Results in Phase 3 AD Trial

Amlitelimab shows promising phase 3 results in treating atopic dermatitis, achieving significant skin clearance and potential for infrequent dosing.

ICYMI: DermaRite Recall Due to Sepsis Risk Expands to Creams, Hair Products

The expanded voluntary recall is due to the potential microbial contamination of Burkholderia cepacia complex.

Clinical Trials Support New Retinal Formulation Tolerability

Discover the benefits of RetaXome therapy for sensitive skin and its potential in skin care routines.

FDA Clears Dermalogica's PRO Pen Microneedling System as a Class II Medical Device

Dermalogica's PRO Pen Microneedling System gains FDA clearance, revolutionizing non-invasive skin treatments with advanced technology and customizable options.

The Cutaneous Connection: Utilizing the NEA's EczemaWise App for Clinicians and Patients

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, discuss the National Eczema Association's EczemaWise app and how it can be used by both clinicians and patients.

Alexa Kimball, MD, on the Future of HS Care

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

A New Perspective on Seborrheic Dermatitis Management

Explore innovative treatments for seborrheic dermatitis, including roflumilast foam, and learn about effective patient-centered care strategies.

Johnson & Johnson Seeks EMA Approval for Oral IL-23 Antagonist Icotrokinra

Phase 3 trials demonstrated that icotrokinra met all primary and co-primary endpoints, including PASI 90 and IGA 0/1 responses.

Upadacitinib Sustains AD Control for 140 Weeks

Upadacitinib maintained high EASI and itch response rates through nearly 3 years of treatment.

How Medium-to-Deep Chemical Peels Tackle Refractory Melasma

Discover how medium-to-deep chemical peels effectively treat refractory melasma, enhancing skin tone and quality with tailored approaches.

Undertreated, Underdiagnosed: Experts Address Genital Psoriasis

New guidelines enhance understanding and treatment of genital psoriasis, addressing its psychological impact and improving patient-provider communication.

Dual-Wavelength Low Power Lasers Increase Photosensitivity Risk in Skin of Color

Darker skin tones face higher risks of photosensitivity and thermal burns during dual-wavelength laser therapy, highlighting the need for tailored treatment approaches.

Impact of Biologic Utilization Management Programs in Atopic Dermatitis

Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.

New Review Explores the Shared Genetic Backgrounds of Cardiovascular Diseases and Psoriasis

Explore the complex genetic links between psoriasis and cardiovascular diseases, highlighting the IL-23 and IL-17 pathways' role in health risks.

Science of Skin & Scalp Studio Highlights Cultural Gaps in Dermatology

Dermatologists and hairstylists unite to address scalp health, cultural practices, and patient care at the Science of Skin & Scalp Studio event.

Cigna Expands Coverage for Home Phototherapy

Cigna’s removal of restrictions on home phototherapy, following a similar decision by Elevance Health, expands access to more than 66 million Americans.